ProMetic's PBI-4050 Shown to Reduce Heart Fibrosis

ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF), ("ProMetic" or the
"Corporation") presented new preclinical data at the 2013 American Society of
Nephrology ("ASN") annual meeting held in Atlanta on November 7-10, 2013. 


Cardiovascular diseases, in their broad spectrum, are collectively the major
cause of death in patients on dialysis. One of the studies performed was to
determine the effect of a permanent vascular catheter on heart fibrosis and to
investigate the potential protective effect of PBI-4050 on the kidneys and the
heart of 5/6 nephrectomised rats. In this study, the nephrectomised rats with a
catheter had 4 times more heart lesions (fibrosis, necrosis and inflammation)
compared to those who did not have a catheter. The rats with catheter and
treated with PBI-4050 had a significant reduction of heart lesions, fibrosis and
collagen compared to the non-treated animals. The nephrectomised rats treated
with PBI-4050 also displayed a significant improvement of their renal function
and a significant reduction of inflammation and fibrosis in their kidneys
compared to the non-treated rats.


"this study is particularly important because it provides a potential mechanism
for reducing the cardiac injury that many patients who use catheters as a
vascular access while on dialysis may experience", stated Dr Raymond Hakim.


Dr. Lyne Gagnon presented an overview of all the pre-clinical data that
demonstrates the ability of PBI-4050 to reduce fibrosis in the kidney and
overall improve the renal function in various animal models; said models ranging
from the uni-nephrectomised diabetic (db/db) mouse model simulating diabetic
nephropathies (DKD) to the 5/6 nephrectomised rat model emulating chronic kidney
disease (CKD) in humans.


"Patients with advanced CKD conditions, whether or not on dialysis, present a
very complex medical profile often involving hypertension, diabetic and
cardiovascular complications. The pre-clinical data strongly suggests that
PBI-4050 could provide a novel approach to modulate the process that leads to a
gradual loss of the renal function in these patients", commented Dr. Raymond
Hakim. 


"These new findings add significant weight to our ultimate strategic positioning
of PBI-4050 going forward", stated Dr John Moran, who added "any beneficial
clinical effect in diabetic patients with chronic kidney diseases ought to be
part of a new clinical mindset when evaluating the performance of a drug".


The Corporation expects to start enrolling patients in early 2014 to demonstrate
efficacy.


The study results presented at the ASN conference are available on the Prometic
website at: http://www.prometic.com/en/therapeutics/conferences.php


About ProMetic Life Sciences Inc. 

ProMetic Life Sciences Inc. (www.prometic.com) is a long established
biopharmaceutical company with globally recognized expertise in bioseparations,
plasma-derived therapeutics and small-molecule drug development. ProMetic offers
its state of the art technologies for large-scale purification of biologics,
drug development, proteomics and the elimination of pathogens to a growing base
of industry leaders and uses its own affinity technology that provides for
highly efficient extraction and purification of therapeutic proteins from human
plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic
is also active in developing its own novel small-molecule therapeutic products
targeting unmet medical needs in the field of fibrosis, cancer and autoimmune
diseases/inflammation. Headquartered in Laval (Canada), ProMetic has R&D
facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK
and business development activities in the U.S., Europe and Asia.


Forward-Looking Statements

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect
our business, or if our estimates or assumptions turn out to be inaccurate. Such
risks and assumptions include, but are not limited to, ProMetic's ability to
develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current
expectations on page 26 of ProMetic's Annual Information Form for the year ended
December 31, 2012, under the heading "Risk and Uncertainties related to
ProMetic's business". As a result, we cannot guarantee that any forward-looking
statement will materialize. We assume no obligation to update any
forward-looking statement even if new information becomes available, as a result
of future events or for any other reason, unless required by applicable
securities laws and regulations. All amounts are in Canadian dollars unless
indicated otherwise.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pierre Laurin
President and CEO
ProMetic Life Sciences Inc.
[e-mail]
+1.450.781.0115


Frederic Dumais
Director, Communications and
Investor Relations
ProMetic Life Sciences
[e-mail]
+1.450.781.0115